Can we talk about price with patients when choosing antiretroviral therapy? A survey with people living with HIV and prescribers in France

Autor: Papot, Emmanuelle, Kalampalikis, Nikos, Doumergue, Marjolaine, Pilorgé, Fabrice, Quatremère, Guillemette, Yazdanpanah, Yazdan, Préau, Marie
Přispěvatelé: Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Université Sorbonne Paris Nord, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Groupe de Recherche en Psychologie Sociale (GRePS), Université Lumière - Lyon 2 (UL2), AIDES [Pantin, France], Radiations : Défense, Santé, Environnement [Lyon] ( Inserm U1296 / UL2), Université Lumière - Lyon 2 (UL2)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Psychologie, ANRS-GOTA study group: Philippe Arnaud, Claire Auger, Franck Barbier, Gaele Bruneaux, Katia Bourdic, Elisabeth Bouvet, Agnès Certain, Charlotte Charpentier, Marjolaine Doumergue, Véronique Doré, Cécile Goujard, Sophia Guessous, Anne-Claire Haye, Nikos Kalampalikis, Roland Landman, Sylvie LeGac, Françoise Louni, David Michels, Philippe Morlat, Dorothée Obach, Emmanuelle Papot, Gilles Peytavin, Fabrice Pilorgé, Laurence Pochat, Marie Préau, Guillemette Quatremère, Daniela Rojas Castro, Yazdan Yazdanpanah, Patrick Yéni, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Radiations : Défense, Santé, Environnement [Lyon] (Inserm UA8), Institut National de la Santé et de la Recherche Médicale (INSERM), Malbec, Odile
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: BMJ Open
BMJ Open, BMJ Publishing Group, 2021, 11 (11), pp.e046212. ⟨10.1136/bmjopen-2020-046212⟩
BMJ Open, 2021, 11 (11), pp.e046212. ⟨10.1136/bmjopen-2020-046212⟩
ISSN: 2044-6055
Popis: International audience; Objective The aim of this study was to evaluate people living with HIV (PLWH) and HIV specialist prescribers' perception of discussing antiretroviral therapy (ART) price in PLWH's care and the acceptability of choosing or switching to various types of less expensive ARTs. Design Cross-sectional surveys (one in a convenience sample of PLWH and one in a voluntary response sample of HIV specialist prescribers). Setting and participants The surveys were conducted among PLHW attending an HIV clinic in the North of Paris (cohort of 4922 PLWH in 2016), and HIV specialists working in French HIV clinics (210 across 12 districts/28), between January and June 2016. Method Self-administered questionnaires were constructed using data collected during focus groups with PLWH and prescribers. Pretests were carried out to select the questions and items. Descriptive analyses of the 129 complete questionnaires of PLWH and 79 of prescribers are presented. Results Among PLWH, 128/129 were on ART and 54% (69/128) gave a fair estimation of the price of their current regimen. Among prescribers, 24% (19/79) thought that their patients knew this price. Taking into account the price of ART was not perceived as a negative step in the history of French response to HIV epidemic for 53% (68/129) of PLWH and 82% (65/79) of prescribers. Seventy-seven PLWH (60%) would agree to switch to less expensive antiretroviral regimens (as effective and with similar adverse events) if pills were bigger; 42 (33%) if there were more daily doses, and 37 (29%) if there were more pills per dose; prescribers were more circumspect. Conclusion A high proportion of PLWH gave a fair estimate of their ART price and this seemed unexpected by HIV specialists. Consideration of drug prices when choosing ART was perceived as conceivable by PLWH and prescribers if effectiveness and tolerance were also considered.
Databáze: OpenAIRE
Externí odkaz: